octocrylene
Approved
Jul 21, 2006
Octocrylene is a compound often used as an additive in sun screen, and is thought to have skin moisturizing effects because of its emollient properties. What makes this chemical such a popular additive to sun block, is its ability to neutralize UV radiation dissipated by sunlight, and to minimize skin damage from prolonged sun exposure. Octocrylene is also often combined with avobenzone, another common sunscreen ingredient often appearing on ingredient labels. Because of its effectiveness, the chemical has been approved across the globe for use in cosmetics and skin care products, but the concentrations of this ingredient are usually limited to no more than 10 or 12 percent. However, the use of this chemical doesn’t just stop with sunscreen for face and arms, but can extend to a variety of other products, like hair spray, tannin oil, BB cream, conditioner, and CC cream, among others. Octocrylene may cause contact and photocontact allergy. — NCATS
Clinical trial activity
7 trials · 8 clinical orgs · 2 marketing orgs
Earliest trial started May 1, 2006 (NCT00326274)
Timeline
2000s
- Jan 1, 2006
- Jan 1, 2006
- Jul 21, 2006
Earliest FDA Approval
- Jul 21, 2006
L'Oreal — NDA Secondary Org
- Jul 21, 2006
Sanofi-Aventis — NDA Secondary Org
- Oct 5, 2006
L'Oreal — First NDA Organization
- Oct 5, 2006
L'Oreal — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Sunscreen
- Unspecified targetUltraviolet filter
ultraviolet filter
Combination products
anthelios
with titanium, avobenzone, ecamsule
anthelios sx
with avobenzone, ecamsule
Also known as capital soleil
Approval history
- approvedJul 21, 2006
Chemistry & pharmacology
SMILES
CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C2=CC=CC=C2- Mol. weight
- 361.4767 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaOctocrylene ↗
- NCATS5A68WGF6WM ↗
- ChEMBLCHEMBL1201147 ↗
Also known as
- 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate
- 2-ethylhexyl 2-cyano-3,3-diphenylacrylate
- octocrilene
- octocrilene
- octocrilene
- octocrylene
- octocrylene
- octocrylene
- octocrylene
- octocrylene
- octocrylene
- octocrylene
- octocrylene
- octocylene
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03012347 | N/A | Jan 1, 2017 | Bayer |
| NCT01826630 | N/A | Jul 31, 2013 | TopMD Skin Care, Inc. |
| NCT01888887 | N/A | Dec 31, 2012 | AMA Laboratories Inc., Galderma |
| NCT01695356 | Phase 4 | Sep 1, 2012 | Universidad Autonoma de San Luis Potosi |
| NCT00530387 | N/A | Jul 1, 2008 | University of Dundee |
| NCT00368563 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2006 | Hill Top Research, L'Oreal |
| NCT00326274 | Phase 3 | May 1, 2006 | L'Oreal |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| L'Oreal | For profit | 2 | 2 | 1 | 2006 |
| AMA Laboratories Inc. | For profit | 1 | 0 | 1 | 2012 |
| Bayer | For profit | 1 | 1 | 1 | 2017 |
| Galderma | For profit | 1 | 1 | 1 | 2012 |
| Hill Top Research | For profit | 1 | 0 | 1 | 2006 |
| TopMD Skin Care, Inc. | For profit | 1 | 1 | 1 | 2013 |
| Universidad Autonoma de San Luis Potosi | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Dundee | Academic/Hospital | 1 | 1 | 1 | 2008 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| L'Oreal | For profit | NDA | Oct 5, 2006 |
| L'Oreal | For profit | NDA2 | Jul 21, 2006 |
| Sanofi-Aventis | For profit | NDA2 | Jul 21, 2006 |